Income Statement

Nexstim's revenue growth in the last quarter has been driven by the increasing adoption of its NBS System 6 diagnostic and therapy systems, particularly in the Diagnostics Business. The company's strategic partnership with Brainlab SE has also contributed to the growth, as it has expanded Nexstim's global distributor network and increased system and service sales volumes. However, the Therapy Business has experienced a decline in revenue, primarily due to the shift towards reusable multi-purpose head trackers, which is expected to be a positive trend in the long run. The Research and Neuroscience Business has shown significant growth, driven by the sale of Nexstim systems and support services to leading research hospitals and clinics. Overall, Nexstim's revenue development is expected to continue its upward trend, driven by the company's innovative technology and strategic partnerships.

The realised revenue for Q2 2026 is 2.6 million Euros, and the predicted revenue for Q2 2027 (e) is 3.0 million Euros. The revenue is expected to increase by 0.4 million Euros, which is a 15.4% change from Q2 2026 to Q2 2027 (e). The revenue is expected to increase by 1.4 million Euros from 2025 to 2026, which is a 12.7% change. From 2026 to 2027, the revenue is predicted to increase by 1.5 million Euros, representing a 11.7% change. The annual revenue values are 11.0 million Euros in 2025, 12.4 million Euros in 2026, and 13.9 million Euros in 2027.

Nexstim's EBIT profitability has shown a significant improvement, indicating a positive trend in the company's operational efficiency. This development can be attributed to the company's successful cost management efforts, which have enabled Nexstim to minimize its expenses while maintaining a stable level of investments in research and development. Additionally, the company's strategic focus on profitable growth has led to a more efficient allocation of resources, resulting in improved profitability. However, the company's EBIT profitability is still impacted by one-off costs related to financing activities, which have had a negative effect on the company's bottom line. Nevertheless, Nexstim's ability to navigate these challenges and maintain a positive EBIT profitability trend is a testament to the company's strong operational management and strategic direction.

The realised Ebit for Q2 2026 is -0.2 million Euros, while the predicted Ebit for Q2 2027 (e) is -0.1 million Euros. The expected change in Ebit from Q2 2026 to Q2 2027 (e) is 0.1 million Euros, which represents a 50% decrease. The expected change in Ebit from 2025 to 2026 is 0.4 million Euros, representing a 66.7% increase. From 2026 to 2027, the expected change is 0.7 million Euros, a 70% increase. The annual Ebit values are 0.6 million Euros in 2025, 1.0 million Euros in 2026, and 1.7 million Euros in 2027.

The realised value of Profit before tax in Q2 2026 is -0.4 million Euros, and the predicted value for Q2 2027 (e) is also -0.4 million Euros. The expected change in Profit before tax from Q2 2026 to Q2 2027 (e) is zero million Euros, which translates to a percentage change of 0%. The profit before tax is expected to decrease by 0.1 million Euros from 2025 to 2026, which is a 16.7% decrease. From 2026 to 2027, the profit before tax is expected to increase by 0.6 million Euros, which is a 120% increase. The annual values for profit before tax are 0.6 million Euros in 2025, 0.5 million Euros in 2026, and 1.1 million Euros in 2027.

The realised profit for Q2 2026 is -0.4 million Euros, and the predicted profit for Q2 2027 (e) is -0.3 million Euros. The expected change in profit from Q2 2026 to Q2 2027 (e) is an increase of 0.1 million Euros, which represents a 25% decrease. The profit is expected to decrease by 0.4 million Euros from 2025 to 2026, which is a 40% decrease. From 2026 to 2027, the profit is expected to increase by 0.7 million Euros, which is a 350% increase. The annual profit values are 0.6 million Euros in 2025, 0.2 million Euros in 2026, and 0.9 million Euros in 2027.